Researchers created a systematic method to design cyclic peptides that survive the gut and enter the bloodstream, demonstrating oral activity against cancer-related integrins in mice.
Oral peptide activityA cyclic hexapeptide designed through systematic N-methylation and prodrug chemistry showed biological effects in mice when given orally
What the researchers found
Researchers developed a systematic method to create cyclic peptides that can be taken orally — solving one of the biggest challenges in peptide drug development. Their approach combined two strategies: (1) N-methylation of the peptide backbone to improve intestinal permeability, and (2) protecting charged groups with lipophilic prodrug modifications to allow absorption.
They applied this to create an orally bioavailable RGD-containing hexapeptide that selectively binds the integrin αvβ3 — a receptor involved in tumor blood vessel growth. The final compound showed biological effects in mice after oral administration, proving the concept works in a living organism. The method involved screening combinatorial libraries for permeability, then systematically optimizing for receptor selectivity and oral absorption.
Why it matters
Most peptide drugs must be injected because they're destroyed in the stomach or can't cross the intestinal wall. Making peptides orally bioavailable would transform the field — imagine taking semaglutide as a simple pill instead of a weekly injection. This study provides a generalizable design framework: cyclize the peptide, selectively N-methylate the backbone, then add prodrug protecting groups. While the specific target here is cancer-related integrins, the methodology could be applied to make many other peptide drugs orally available.
The numbers in context
6-amino acid cyclic peptide · systematic N-methylation library screening · RGD sequence for integrin binding · selective for αvβ3 · oral activity confirmed in mice · published in Angewandte Chemie
How the study worked
Seven-step systematic approach: (1) designed a combinatorial library of N-methylated cyclic hexapeptide analogs, (2) selected peptides with highest intestinal permeability, (3) designed sublibraries incorporating the bioactive RGD sequence in all possible positions, (4) selected best integrin αvβ3 ligands, (5) fine-tuned affinity and selectivity via additional amino acid substitutions, (6) applied lipophilic prodrug protecting groups to restore oral permeability, (7) demonstrated biological activity in mice after oral dosing.
Who was studied
Not applicable (peptide chemistry study with mouse proof-of-concept)
What this study cannot tell us
The method was demonstrated for cyclic hexapeptides targeting one specific receptor — it remains to be seen how broadly this approach generalizes to other peptide targets and sizes. The prodrug protecting groups must be cleaved in vivo to release the active peptide, and this conversion efficiency may vary. The mouse proof-of-concept does not establish therapeutic efficacy or safety. Manufacturing complexity of N-methylated cyclic prodrug peptides could be a barrier to clinical development.
How to read the evidence
Published in Angewandte Chemie — a top-tier chemistry journal — this study presents an innovative and systematic approach validated with mouse proof-of-concept. The 'Moderate' grade reflects the strong chemistry but early-stage biological validation.
When this study was published
Published in 2017, this study represents an important contribution to the oral peptide design field. The approach has influenced subsequent work on cyclic peptide drug development and oral bioavailability engineering.
The bigger picture
The quest for oral peptide drugs is one of the most active areas in pharmaceutical research. Oral semaglutide (Rybelsus) proved it's possible with an absorption enhancer approach, but that method is specific to one drug. This study offers a more generalizable peptide engineering strategy — cyclization plus N-methylation plus prodrug chemistry — that could be a template for making many different peptide drugs orally available. If successful, it could shift peptide therapeutics from injection-dependent to pill-based.
Questions still open
- Can this N-methylation plus prodrug approach be scaled to peptides larger than hexapeptides?
- How does the oral bioavailability of these engineered cyclic peptides compare to oral semaglutide's absorption-enhancer approach?
- Could this method be applied to make existing injectable peptide drugs (like GLP-1 agonists or growth hormone peptides) into oral formulations?
Common questions
Why is it so hard to take peptides by mouth?
How is this different from how oral semaglutide (Rybelsus) works?
Read the original research
Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.
Angewandte Chemie (International ed. in English), 56(51), 16405-16409
Citation
Weinmüller, Michael; Rechenmacher, Florian; Kiran Marelli, Udaya; Reichart, Florian; Kapp, Tobias G; Räder, Andreas F B; Di Leva, Francesco Saverio; Marinelli, Luciana; Novellino, Ettore; Muñoz-Félix, José M; Hodivala-Dilke, Kairbaan; Schumacher, Adi; Fanous, Joseph; Gilon, Chaim; Hoffman, Amnon; Kessler, Horst. (2017). Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.. Angewandte Chemie (International ed. in English), 56(51), 16405-16409. https://doi.org/10.1002/anie.201709709